Compounds and uses thereof in modulating amyloid beta

Details Compounds and uses thereof in modulating amyloid beta Compounds and uses thereof in modulating amyloid beta

2007-07-17

2007-07-17

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S365000, C514S397000, C514S383000, C548S202000, C548S255000, C548S311100, C548S364100, C544S333000

Reexamination Certificate

active

10846941

ABSTRACT:
Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: RE28819 (1976-05-01), Thompson
patent: 4044126 (1977-08-01), Cook et al.
patent: 4328245 (1982-05-01), Yu et al.
patent: 4358603 (1982-11-01), Yu
patent: 4364923 (1982-12-01), Cook et al.
patent: 4409239 (1983-10-01), Yu
patent: 4410545 (1983-10-01), Yu et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 5033252 (1991-07-01), Carter
patent: 5052558 (1991-10-01), Carter
patent: 5323907 (1994-06-01), Kalvelage
patent: 5387742 (1995-02-01), Cordell
patent: 5594010 (1997-01-01), Fey et al.
patent: 5612486 (1997-03-01), McConologue et al.
patent: 5672805 (1997-09-01), Neve
patent: 5709874 (1998-01-01), Hanson et al.
patent: 5759542 (1998-06-01), Gurewich
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5840674 (1998-11-01), Yatvin et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5860957 (1999-01-01), Jacobsen et al.
patent: 5900252 (1999-05-01), Calanchi et al.
patent: 5948433 (1999-09-01), Burton et al.
patent: 5972366 (1999-10-01), Haynes et al.
patent: 5983134 (1999-11-01), Ostrow
patent: 5985307 (1999-11-01), Hanson et al.
patent: 5985317 (1999-11-01), Venkateshwaran et al.
patent: 6004534 (1999-12-01), Langer et al.
patent: 6010715 (2000-01-01), Wick et al.
patent: 6024975 (2000-02-01), D'Angelo et al.
patent: 6037521 (2000-03-01), Sato et al.
patent: 6039975 (2000-03-01), Shah et al.
patent: 6048736 (2000-04-01), Kosak
patent: 6060082 (2000-05-01), Chen et al.
patent: 6071495 (2000-06-01), Unger et al.
patent: 6120751 (2000-09-01), Unger
patent: 6131570 (2000-10-01), Schuster et al.
patent: 6139865 (2000-10-01), Friend et al.
patent: 6167301 (2000-12-01), Flower et al.
patent: 6184435 (2001-02-01), Benson et al.
patent: 6187992 (2001-02-01), Zheng et al.
patent: 6211428 (2001-04-01), Singh et al.
patent: 6253872 (2001-07-01), Neumann
patent: 6256533 (2001-07-01), Yuzhakov et al.
patent: 6261595 (2001-07-01), Stanley et al.
patent: 6267983 (2001-07-01), Fujii et al.
patent: 6271359 (2001-08-01), Norris et al.
patent: 6274552 (2001-08-01), Tamarkin et al.
patent: 6316652 (2001-11-01), Steliou
patent: 6340783 (2002-01-01), Snow
patent: 6562817 (2003-05-01), Tanimoto et al.
patent: 2003/0158199 (2003-08-01), Stieber et al.
patent: 2003-313176 (2003-11-01), None
patent: WO 97/36898 (1997-10-01), None
patent: WO 2004/018997 (2004-03-01), None
Dhar et al., “A Survey of Cyclic Replacements for the Central Diamide Moiety of Inhibitors of Inosine Monophosphate Dehydrogenase.”Bioorganic&Medicinal Chemistry Letters, 12:3125-3128, (2002).
Emilien, et al., “Prospects for Pharmacological Intervention in Alzheimer Disease.”Arch. Neuro. 57:176-181, (2000).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein.”Nature373:523-527, (1995).
Harris et al., “Discovery and evaluation of 2-Anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.” Journal of Medicinal Chemistry, Web release Feb. 9, 2005.
Klunk et al. “Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systematically Administered Congo Red Derivative.”J. Neuropathol. Exp. Neurol.61:797-805, (2002).
Mathis et al., “A Lipophilic Thioflavin-T Derivative for Positron emmision tomography (PET) Imaging of Amyloid in Brain.”Bioorg. Med. Chem. Lett.12:295-298, (2002).
Neve et al., “Transgenic Mice Expressing APP-C100 in the Brain.”Neurobiol. Aging17:191-203, (1996).
Wiltfang et al., “Elevation of β-Amyloid Peptide 2-42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells.”J. Biol. Chem., 276: 42645-42657, (2001).
International Search Report and Written Opinion from corresponding PCT Application No. PCT/US04/15239.

Affiliated with

Also associated with

Rating

Compounds and uses thereof in modulating amyloid beta does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and uses thereof in modulating amyloid beta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and uses thereof in modulating amyloid beta will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754194